Clinical and therapeutic implications of follistatin in solid tumours

Shi, Lei, Resaul, Jeyna, Owen, Sioned, Ye, Lin ORCID: https://orcid.org/0000-0002-0303-2409 and Jiang, Wen ORCID: https://orcid.org/0000-0002-3283-1111 2016. Clinical and therapeutic implications of follistatin in solid tumours. Cancer Genomics and Proteomics 13 (6) , pp. 425-435.

Preview

PDF - Published Version Download (547kB) | Preview

Abstract

Follistatin (FST), as a single-chain glycosylated protein, has two major isoforms, FST288 and FST315. The FST315 isoform is the predominant form whilst the FST288 variant accounts for less than 5% of the encoded mRNA. FST is differentially expressed in human tissues and aberrant expression has been observed in a variety of solid tumours, including gonadal, gastric and lung cancer, hepatocellular carcinoma, basal cell carcinoma and melanoma. Based on the current evidence, FST is an antagonist of transforming growth factor beta family members, such as activin and bone morphogenetic proteins (BMPs). FST plays a role in tumourigenesis, metastasis and angiogenesis of solid tumours through its interaction with activin and BMPs, thus resulting in pathophysiological function. In terms of diagnosis, prognosis and therapy FST has shown strong promise. Through a better understanding of its biological functions, potential clinical applications may yet emerge.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Subjects:	R Medicine > R Medicine (General)
Uncontrolled Keywords:	Follistatin, activin, bone morphogenic protein and cancer, review.
Publisher:	International Institute of Anticancer Research
ISSN:	1109-6535
Funders:	Cancer Research Wales, Cardiff China Medical Scholarship
Date of First Compliant Deposit:	31 October 2016
Date of Acceptance:	5 October 2016
Last Modified:	31 Aug 2023 03:32
URI:	https://orca.cardiff.ac.uk/id/eprint/95716

Citation Data

Cited 24 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item